title: Use of testosterone to prevent cyclophosphamide-induced azoospermia.
abstract: BACKGROUND
  Prepubertal patients receiving chemotherapy are relatively resistant to cyclophosphamide-induced germinal cell alterations.
  
  
  OBJECTIVE
  To study the possible protective effect of testosterone used to inhibit germinal cell activity in men who are receiving cyclophosphamide.
  
  
  METHODS
  Randomized, clinical trial.
  
  
  METHODS
  University medical center.
  
  
  METHODS
  15 patients with the nephrotic syndrome who were treated with cyclophosphamide for 6 to 8 months.
  
  
  METHODS
  Five patients received daily oral cyclophosphamide, five received cyclophosphamide in monthly bolus injections, and five received monthly intravenous boluses of cyclophosphamide plus testosterone (100 mg intramuscularly every 15 days).
  
  
  METHODS
  Sperm counts, serum follicle-stimulating hormone levels, and serum luteinizing hormone levels were measured before, during, and after treatment with cyclophosphamide alone or cyclophosphamide plus testosterone.
  
  
  RESULTS
  The 10 patients who did not receive testosterone became azoospermic during cyclophosphamide therapy. In only 1 of the 10 patients did the sperm count return to normal 6 months after discontinuation of therapy. Follicle-stimulating hormone levels were elevated in these patients (mean +/- SE, 19.20 +/- 1.28 IU/L in patients receiving oral cyclophosphamide and 16.04 +/- 2.22 IU/L in patients receiving intravenous cyclophosphamide alone). All 5 patients who received testosterone became azoospermic or severely oligospermic during treatment but had a normal sperm count 6 months after the discontinuation of therapy. In these patients, the mean sperm count was 45.78 +/- 3.89 x 10(6)/mL and follicle-stimulating hormone levels were normal (5.08 +/- 0.56 IU/L).
  
  
  CONCLUSIONS
  Testosterone given to men before and during an 8-month cycle of cyclophosphamide therapy for the nephrotic syndrome may preserve fertility.
authors.affiliation: University of Sassari, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Masala
authors.forename: R
authors.initials: R
authors.lastname: Faedda
authors.forename: S
authors.initials: S
authors.lastname: Alagna
authors.forename: A
authors.initials: A
authors.lastname: Satta
authors.forename: G
authors.initials: G
authors.lastname: Chiarelli
authors.forename: P P
authors.initials: PP
authors.lastname: Rovasio
authors.forename: R
authors.initials: R
authors.lastname: Ivaldi
authors.forename: M S
authors.initials: MS
authors.lastname: Taras
authors.forename: E
authors.initials: E
authors.lastname: Lai
authors.forename: E
authors.initials: E
authors.lastname: Bartoli
mesh_terms: D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy; D009845:Oligospermia / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control*; D011446:Prospective Studies; D013076:Sperm Count / Q000187:drug effects; D013739:Testosterone / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D013739:Testosterone; D003520:Cyclophosphamide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone